FPS
SAGE

Fieldpoint Private Securities’s Sage Therapeutics SAGE Stock Holding History

Fieldpoint Private Securities’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,260
Closed -$163K – 501
2019
Q4 		$163K Buy
2,260
+1,388
+159% +$171K 0.05% 287
2019
Q3 		$122K Sell
872
-74
-8% -$12.4K 0.04% 260
2019
Q2 		$173K Buy
+946
New +$161K 0.05% 248

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Fieldpoint Private Securities's SAGE Position: Q1 2020 in Review

Fieldpoint Private Securities sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 2,260 shares — an estimated $163K sold.

Fieldpoint Private Securities first reported a position in SAGE in Q2 2019 and held it in 3 quarters. The position peaked at $173K in Q2 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

  • Fieldpoint Private Securities reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Fieldpoint Private Securities sold 2,260 Sage Therapeutics shares in Q1 2020, an estimated $163K.
  • Fieldpoint Private Securities first reported a position in Sage Therapeutics in Q2 2019 and held it in 3 quarters.
  • Fieldpoint Private Securities's Sage Therapeutics position peaked at $173K in Q2 2019.
  • 229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on Fieldpoint Private Securities's 13F filing for Q1 2020, filed 11 May 2020.